Hypertonic Saline for Nontuberculous Mycobacterial Lung Disease

Recruiting at2 trial locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Recruiting

Sponsor: Oregon Health and Science University

Must not be taking: Bedaquiline, Macrolide, Ethambutol, Rifampin

Disqualifiers: HIV, Cystic fibrosis, Tuberculosis, others

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial is testing whether inhaling a saltwater solution can help patients with a specific lung infection by making it easier to clear mucus from their lungs. Saltwater solutions have been used to improve mucus clearance in conditions like cystic fibrosis and chronic bronchitis.

Will I have to stop taking my current medications?

The trial requires that you have not taken certain medications for MAC treatment, like bedaquiline or a combination of macrolide, ethambutol, and rifampin, in the past 6 months. If you are currently on these medications, you would need to stop them to participate.

What data supports the effectiveness of the drugs used in the treatment for Nontuberculous Mycobacterial Lung Disease?

Research shows that ethambutol is effective in reducing mycobacterial levels in patients with Mycobacterium avium complex infections, and it is often used in combination with other drugs like rifampin and azithromycin to treat similar infections. ^{1 2 3 4 5}

Is hypertonic saline safe for treating nontuberculous mycobacterial lung disease?

The safety of hypertonic saline specifically for nontuberculous mycobacterial lung disease isn't directly addressed in the provided studies. However, some antibiotics like rifabutin, when used in combination with others, have shown adverse effects such as severe neutropenia (low white blood cell count) and gastrointestinal symptoms, indicating the importance of monitoring for side effects during treatment. ^{1 4 5 6 7}

What makes the drug combination of Azithromycin, Ethambutol, Hypertonic Saline, and Rifampin unique for treating nontuberculous mycobacterial lung disease?

This drug combination is unique because it includes hypertonic saline, which is not typically used in standard treatments for nontuberculous mycobacterial lung disease. Hypertonic saline may help clear mucus from the lungs, potentially enhancing the effectiveness of the antibiotics Azithromycin, Ethambutol, and Rifampin, which are known to be active against various mycobacterial infections. ^{1 4 8 9 10}

Research Team

Eligibility Criteria

This trial is for adults over 18 with M. avium complex lung infections who meet specific lung disease criteria and have had at least two positive MAC sputum cultures in the past year. It's not for those with HIV, cystic fibrosis, certain NTM diseases, active tuberculosis or fungal infections, high-dose steroid users, organ transplant recipients, or anyone unable to consent.

Inclusion Criteria

Ability to provide informed consent

You have symptoms that match the guidelines for diagnosing lung diseases set by the American Thoracic Society and Infectious Disease Society of America in 2007.

I am 18 years old or older.

Exclusion Criteria

I have been taking more than 15 mg/day of corticosteroids for over 3 months.

I have been diagnosed with HIV.

I have been diagnosed with Cystic Fibrosis.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants are randomized to receive either hypertonic saline or standard of care for 12 weeks. The treatment group takes inhaled hypertonic saline twice daily.

12 weeks

Regular visits for monitoring and assessments

Follow-up

Participants are monitored for safety and effectiveness after treatment, including final visit, sputum collection, and AE assessment.

4 weeks

Treatment Details

Interventions

• Azithromycin (Antibiotic)
• Ethambutol (Antibiotic)
• Hypertonic Saline (Other)
• Rifampin (Antibiotic)

Trial Overview The study examines if inhaling hypertonic saline can help reduce symptoms and improve mycobacteria clearance in patients with M. avium complex lung disease. Participants will also receive standard treatments like Azithromycin, Ethambutol, and Rifampin.

Participant Groups

Group I: Hypertonic saline Experimental Treatment 1 Intervention

Patients who randomize to the hypertonic saline arm will be prescribed a nebulizer device to nebulize hypertonic saline (7%) twice daily for 12 weeks. Hypertonic saline (3%) can be prescribed in the case of poor tolerability of the 7% solution.

Group II: Standard of Care Active Control 3 Interventions

Patients who randomize to the standard of care arm will receive treatment for pulmonary MAC based on the approved ATS/IDSA guidelines. Changes to standard of care regimen may be made based on the investigator's discretion.

Azithromycin is already approved in Canada for the following indications:

Approved in Canada as Azithromycin for:

• Respiratory tract infections
• Skin and soft tissue infections
• Sexually transmitted diseases
• Toxoplasmosis
• Malaria
• Preterm prelabor rupture of membranes

Who Is Running the Clinical Trial?

Oregon Health and Science University

Lead Sponsor

Trials

1,024

Recruited

7,420,000+

John Hunter

Oregon Health and Science University

Chief Medical Officer since 2024

MD, specific details unavailable

Ann Madden Rice

Oregon Health and Science University

Chief Executive Officer

FACHE certification, extensive leadership experience in academic health centers

New York University

Collaborator

Trials

249

Recruited

229,000+

Dr. Fritz François

New York University

Chief Medical Officer

MD from NYU Grossman School of Medicine

Dr. Robert I. Grossman

New York University

Chief Executive Officer since 2007

MD from NYU Grossman School of Medicine

NTM Info & Research, Inc.

Collaborator

Trials

1

Recruited

50+

University Health Network, Toronto

Collaborator

Trials

1,555

Recruited

526,000+

Dr. Brad Wouters

University Health Network, Toronto

Chief Medical Officer since 2020

MD from University of Toronto

Dr. Kevin Smith

University Health Network, Toronto

Chief Executive Officer since 2018

Professor at McMaster University and University of Toronto

Findings from Research

In a study involving congenitally athymic (nude) mice, the antibiotics rifapentine, azithromycin, and ethambutol were found to be highly effective against Mycobacterium kansasii when administered individually.

However, when these drugs were used in combination, they did not show increased effectiveness compared to their individual use, indicating that combining these therapies may not provide additional benefits.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Treatment alternatives for Mycobacterium kansasii. Graybill, JR., Bocanegra, R.[2019]

In two cases of Mycobacterium avium-intracellulare complex (MAC) infections, one child with AIDS died despite treatment, highlighting the challenges in managing MAC in immunocompromised patients.

The second child, without immunodeficiency, successfully recovered from a MAC-related mass after a combination therapy including streptomycin, ethambutol, clofazimine, and rifabutin, demonstrating that aggressive multidrug therapy can be effective in non-immunocompromised individuals.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Treatment of nontuberculous mycobacterial infections in pediatric patients. Levin, RH., Bolinger, AM.[2013]

In a study of 119 patients with Mycobacterium avium complex lung disease, the two-drug regimen of clarithromycin and ethambutol resulted in a higher rate of sputum culture conversion (55.0%) compared to the three-drug regimen that included rifampicin (40.6%).

The incidence of adverse events leading to treatment discontinuation was higher in the three-drug group (37.2%) compared to the two-drug group (26.6%), suggesting that the simpler regimen may be safer and equally effective.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study. Miwa, S., Shirai, M., Toyoshima, M., et al.[2014]

In a study using inbred C57BL/6 mice and a macrophage model, the combination of rifabutin, clarithromycin, and ethambutol showed the best results against the Mycobacterium avium strain 101, indicating that combination therapy may enhance efficacy.

However, for strain 2-151, the combination therapy did not significantly outperform clarithromycin alone, suggesting that the effectiveness of drug combinations can vary depending on the specific strain of bacteria being targeted.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Activities of rifabutin, clarithromycin, and ethambutol against two virulent strains of Mycobacterium avium in a mouse model. Furney, SK., Skinner, PS., Farrer, J., et al.[2021]

In a study of 60 HIV-infected patients with Mycobacterium avium complex bacteremia, ethambutol was the only drug that significantly reduced mycobacteremia levels after 4 weeks of treatment, showing a median decrease of -0.60 log10 cfu/mL.

Clofazimine and rifampin did not demonstrate significant antibacterial activity against M. avium complex, with changes in colony counts being minimal, indicating that ethambutol should be prioritized in treatment regimens for this infection.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol, and rifampin, on Mycobacterium avium complex bacteremia in patients with AIDS. Kemper, CA., Havlir, D., Haghighat, D., et al.[2019]

In a 14-day clinical trial with 30 healthy volunteers, the combination of rifabutin with clarithromycin led to significantly increased levels of rifabutin and its active metabolite, raising concerns about potential drug interactions.

Severe neutropenia was observed in 14 participants receiving rifabutin, particularly in those also taking azithromycin or clarithromycin, highlighting the need for careful monitoring of blood cell counts in patients on rifabutin therapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers. Apseloff, G., Foulds, G., LaBoy-Goral, L., et al.[2013]

In a trial involving 26 patients with pulmonary Mycobacterium avium complex (MAC) disease, high-dose rifabutin (600 mg/d) led to adverse events in 77% of participants, with 58% needing dosage adjustments or discontinuation due to side effects.

The most significant adverse effects included a substantial drop in white blood cell counts and gastrointestinal symptoms, prompting a recommendation to lower the rifabutin dose to 300 mg/d when used with macrolides for safer treatment outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Griffith, DE., Brown, BA., Girard, WM., et al.[2019]

Azithromycin demonstrated effective in-vitro activity against Mycobacterium avium complex, with a minimum inhibitory concentration (MIC90) of 32 mg/L, suggesting its potential use in treating infections caused by this non-tuberculous mycobacterium.

The drug showed no effectiveness against Mycobacterium tuberculosis and Mycobacterium marinum, indicating that its therapeutic benefits may be limited to specific types of mycobacterial infections, particularly in patients with AIDS.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Comparative activity of azithromycin against clinical isolates of mycobacteria. Watt, B., Rayner, A., Harris, G.[2019]

A 46-year-old male with a rare congenital lung disease developed Nontuberculous Mycobacteria (NTM) pulmonary disease, highlighting the risk for patients with structural lung issues.

After 16 months of treatment with a combination of antibiotics, including azithromycin and rifampin, the patient achieved culture conversion at 4 months and showed no recurrence of NTM disease for 6 months, indicating the efficacy of the treatment regimen.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Nontuberculous mycobacterial pulmonary disease in a patient with unilateral pulmonary artery agenesis: Case report. Yoon, CS., Park, HK., Lee, JK., et al.[2023]

In a study of 111 patients with pulmonary Mycobacterium avium complex (MAC) disease treated with clarithromycin, 75.7% had a good short-term response, and 82.0% achieved good long-term outcomes, indicating the treatment's overall efficacy.

Short-term treatment responses were particularly predictive of long-term outcomes for patients with large lesions, suggesting that monitoring early responses could help tailor longer treatment plans for better results.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Efficacy and outcomes of clarithromycin treatment for pulmonary MAC disease. Fujikane, T., Fujiuchi, S., Yamazaki, Y., et al.[2013]

References

1. England pubmed.ncbi.nlm.nih.gov

Treatment alternatives for Mycobacterium kansasii. [2019]

2. United States pubmed.ncbi.nlm.nih.gov

Treatment of nontuberculous mycobacterial infections in pediatric patients. [2013]

3. United States pubmed.ncbi.nlm.nih.gov

Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study. [2014]

4. United States pubmed.ncbi.nlm.nih.gov

Activities of rifabutin, clarithromycin, and ethambutol against two virulent strains of Mycobacterium avium in a mouse model. [2021]

5. United States pubmed.ncbi.nlm.nih.gov

The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol, and rifampin, on Mycobacterium avium complex bacteremia in patients with AIDS. [2019]

6. England pubmed.ncbi.nlm.nih.gov

Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers. [2013]

7. United States pubmed.ncbi.nlm.nih.gov

Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. [2019]

8. England pubmed.ncbi.nlm.nih.gov

Comparative activity of azithromycin against clinical isolates of mycobacteria. [2019]

9. England pubmed.ncbi.nlm.nih.gov

Nontuberculous mycobacterial pulmonary disease in a patient with unilateral pulmonary artery agenesis: Case report. [2023]

10. France pubmed.ncbi.nlm.nih.gov

Efficacy and outcomes of clarithromycin treatment for pulmonary MAC disease. [2013]